Participants were adults with: Obesity (BMI 30 kg/m) or Overweight (BMI 27 kg/m) with at least one weight-related comorbidity such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease No diabetes diagnosis Participants were randomized 1:1 to receive either: Maximum tolerated dose of Zepbound (10 mg or 15 mg) Maximum tolerated dose of Wegovy (1.7 mg or 2.4 mg) The study cohort had a mean age of 44.7 years, 64.7% were women, and participants had an average body weight of 249 pounds with a mean BMI of 39.4 kg/m
Some people also explore lipotropic peptide formulations to support fat metabolism during transitions
The risk of risk for recurrence was reduced from 1.7% to 1.5%, or an 18% reduction in risk
the underlying cellular environment, oxidative stress, mitochondrial function, and detoxification capacity, shapes how you age and how well you respond to every other treatment
DOI: 10.1016/0003-9861(85)90282-6 38
